Bristol Myers Squibb reported a higher-than-expected third-quarter profit on Thursday, citing strong sales of established ...

Bristol Myers Squibb’s third-quarter results benefited from sales of its legacy brands Eliquis and Revlimid, as well as ...

Bristol Myers Squibb reported third-quarter earnings and revenue that blew past expectations on strong sales from its blood thinner Eliquis and a portfolio of drugs it expects to deliver long-term ...

Legacy Portfolio revenues were primarily driven by higher demand for Eliquis, partially offset by a decline in demand for Sprycel due to generic erosion. Eliquis sales reached $3 billion from $2. ...

Vyndaqel family drugs generated sales of $1.45 billion, up 62%. Eliquis, a blood thinner drug, generated sales of $1.62 billion, up 8%. Global revenues of $854 million came from legacy Seagen ...

At that point in his life, Scheibel took no daily medication other than a small cholesterol pill, and didn't like having to take a blood thinner called Eliquis twice a day. When Thosani proposed ...

Bristol Myers Squibb exceeded third-quarter profit expectations with $3.7 billion earnings, due to strong sales in established and new drugs. Revenue climbed 8%, hitting $11.89 billion. However, the ...

On Thursday, Bristol Myers Squibb & Co (NYSE:BMY) posted third-quarter revenues of $11.89 billion, beating the consensus of ...